SATURDAY, December 6th

Program: Oral and Poster Abstracts
Session: 623. Lymphoma: Chemotherapy, excluding Pre-Clinical Models: Poster I
Trial: NCIC CTG LY.12
Abstract: **Addition of Rituximab to Salvage Chemotherapy in Aggressive CD20+ Lymphoma Prior to Autologous Stem Cell Transplant (ASCT): A Cohort Comparison from the NCIC CTG Study LY.12**


Time: 5:30 PM-7:30 PM
Location: West Building, Level 1 (Moscone Center)

TUESDAY, December 9th

Program: General Sessions
Session: Late Breaking Abstracts
Trial: NCIC CTG MDC.1 (SWOG S1117)
Abstract: **A Randomized Phase II Study of Azacitidine Combined with Lenalidomide or with Vorinostat Vs. Azacitidine Monotherapy in Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML): North American Intergroup Study SWOG S1117**

Mikkael A. Sekeres, MD, MS, Megan Othus, PhD*, Alan F. List, MD, Olatoyosi Odenike, MD, Richard M. Stone, MD, Steven D. Gore, MD, Mark R. Litzow, MD, Rena Buckstein, MD, Mario r Velasco Jr., M.D., Rakesh Gaur, MD, Ehab Atallah, MD, Eyal Attar, MD, Frederick R. Appelbaum, MD and Harry P. Erba, MD, PhD

Time: 7:30 - 9:00 AM
Location: North Building, Hall D (Moscone Center)